Phio Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that CEO Robert Bitterman will present an overview of its INTASYL siRNA gene silencing technology and its lead clinical candidate PH-762, aimed at treating skin cancers like cutaneous carcinomas. The presentation will take place on July 28, 2026, at 12 PM EDT during a virtual non-deal roadshow hosted by Renmark Financial. PH-762 is designed to silence the PD-1 gene to enhance immune response against cancer cells and is currently in Phase 1b trials. This event offers investors insight into Phio's innovative approach to immuno-oncology and the potential of its technology to advance cancer treatments.
SpaceX shares have fallen 33% from their highest point, reflecting market volatility or investor concerns. Despite this, Elon Musk projects a massive revenue increase for the company, expecting it to grow 53-fold and reach $1 trillion by 2030. This a...
In early 2026, real-world assets (RWAs) attracted 169,000 new wallets on Hyperliquid, accounting for nearly 32% of its new user base. This trend highlights growing interest in RWA-linked markets, with over 80% of these users continuing to engage in R...
Strategy, a major Bitcoin treasury firm, opposes MSCI's new proposal to exclude it and similar crypto asset holders from global indexes. The firm argues that digital assets are legitimate assets and that MSCI should not decide which assets companies ...
Financial Institutions, Inc. (FISI), the holding company for Five Star Bank, maintains a Buy rating due to improved profitability and stronger capital ratios. Its net interest margin rose to 3.70% in Q2 2026, supported by lower funding costs and high...
The Federated Hermes US Strategic Dividend ETF (FDV) remains rated as a 'hold' because it underperforms compared to its peers and faces concerns over the quality and growth of its holdings. Although FDV offers an estimated dividend yield of 3.05%, it...
